IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables
Ji, Li-Nong1; Lu, Ju-Ming2; Guo, Xiao-Hui3; Yang, Wen-Ying4; Weng, Jian-Ping5; Jia, Wei-Ping6; Zou, Da-Jin7; Zhou, Zhi-Guang8; Yu, De-Min9; Liu, Jie10; Shan, Zhong-Yan11; Yang, Yu-Zhi12; Hu, Ren-Ming13; Zhu, Da-Long14; Yang, Li-Yong15; Chen, Li16; Zhao, Zhi-Gang17; Li, Qi-Fu18; Tian, Hao-Ming19; Ji, Qiu-He20; Liu, Jing21; Ge, Jia-Pu22; Shi, Li-Xin23; Xu, Yan-Cheng24
关键词China Glp-1 Receptor Agonists Hba1c Insulin Oral Antidiabetes Drugs (Oads) Type 2 Diabetes Mellitus
刊名BMC PUBLIC HEALTH
2013-06-21
DOI10.1186/1471-2458-13-602
13
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Public, Environmental & Occupational Health
资助者Novo Nordisk (China) Pharmaceutical Co., Ltd (NNCP) ; Novo Nordisk (China) Pharmaceutical Co., Ltd (NNCP)
研究领域[WOS]Public, Environmental & Occupational Health
关键词[WOS]BLOOD-GLUCOSE CONTROL ; ANTIDIABETIC DRUGS ; MANAGEMENT ; COMPLICATIONS ; DETERMINANTS ; ASSOCIATION ; STATEMENT ; COLLEGE ; IDMPS
英文摘要

Background: The prevalence of type 2 diabetes mellitus (T2DM) is increasing rapidly among Chinese adults, and limited data are available on T2DM management and the status of glycemic control in China. We assessed the efficacy of oral antidiabetes drugs (OADs), glucagon-like peptide-1 (GLP-1) receptor agonists, and insulin for treatment of T2DM across multiple regions in China.

Methods: This was a multicenter, cross-sectional survey of outpatients conducted in 606 hospitals across China. Data from all the patients were collected between April and June, 2011.

Results: A total of 238,639 patients were included in the survey. Eligible patients were treated with either OADs alone (n=157,212 [65.88%]), OADs plus insulin (n=80,973 [33.93%]), or OADs plus GLP-1 receptor agonists (n=454 [0.19%]). The OAD monotherapy, OAD + insulin, and OAD + GLP-1 receptor agonist groups had mean glycosylated hemoglobin (HbA1c) levels (+/- SD) of 7.67% (+/- 1.58%), 8.21% (+/- 1.91%), and 7.80% (+/- 1.76%), respectively. Among those three groups, 34.63%, 26.21%, and 36.12% met the goal of HbA1c <7.0%, respectively. Mean HbA1c and achievement of A1c <7.0% was related to the duration of T2DM.

Conclusions: Less than one third of the patients had achieved the goal of HbA1c <7.0%. Glycemic control decreased and insulin use increased with the duration of diabetes.

语种英语
资助者Novo Nordisk (China) Pharmaceutical Co., Ltd (NNCP) ; Novo Nordisk (China) Pharmaceutical Co., Ltd (NNCP)
WOS记录号WOS:000322516400001
Citation statistics
Cited Times:38[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51664
Collection北京大学第二临床医学院
作者单位1.Peking Univ, Hosp 1, Dept Endocrinol, Beijing, Peoples R China
2.Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100044, Peoples R China
3.Chinese Peoples Liberat Army Gen Hosp, Dept Endocrinol, Beijing, Peoples R China
4.China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China
5.Sun Yat Sen Univ, Affiliated Hosp 3, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China
6.Shanghai Sixth Peoples Hosp, Dept Endocrinol, Shanghai, Peoples R China
7.Second Mil Med Univ, Changhai Hosp, Dept Endocrinol, Shanghai, Peoples R China
8.Cent S Univ, Xiangya Hosp 2, Dept Endocrinol, Changsha, Hunan, Peoples R China
9.Tianjin Med Univ, Metab Dis Hosp, Dept Endocrinol, Tianjin, Peoples R China
10.Shanxi Prov Peoples Hosp, Dept Endocrinol, Taiyuan, Peoples R China
11.China Med Univ, Hosp 1, Dept Endocrinol, Shenyang, Peoples R China
12.Heilongjiang Prov Hosp, Dept Endocrinol, Harbin, Peoples R China
13.Fudan Univ, Huashan Hosp, Dept Endocrinol, Shanghai 200433, Peoples R China
14.Nanjing Univ, Sch Med, Affiliated Hosp, Dept Endocrinol,Nanjing Drum Tower Hosp, Nanjing 210008, Jiangsu, Peoples R China
15.Fujian Med Univ, Affiliated Hosp 1, Dept Endocrinol, Fuzhou, Peoples R China
16.Shandong Univ, Qilu Hosp, Dept Endocrinol, Jinan 250100, Peoples R China
17.Henan Prov Peoples Hosp, Dept Endocrinol, Zhengzhou, Peoples R China
18.Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrinol, Chongqing, Peoples R China
19.Gansu Prov Hosp, Dept Endocrinol, Lanzhou, Peoples R China
20.Sichuan Univ, West China Hosp, Dept Endocrinol, Chengdu 610064, Peoples R China
21.Fourth Mil Med Univ, Xijing Hosp, Dept Endocrinol, Xian 710032, Peoples R China
22.Xinjiang Uigur Autonomous Reg Peoples Hosp, Dept Endocrinol, Urumqi, Peoples R China
23.Guiyang Med Coll, Affiliated Hosp, Dept Endocrinol, Guiyang, Peoples R China
24.Wuhan Univ, Zhongnan Hosp, Dept Endocrinol, Wuhan 430072, Peoples R China
Recommended Citation
GB/T 7714
Ji, Li-Nong,Lu, Ju-Ming,Guo, Xiao-Hui,et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables[J]. BMC PUBLIC HEALTH,2013,13.
APA Ji, Li-Nong.,Lu, Ju-Ming.,Guo, Xiao-Hui.,Yang, Wen-Ying.,Weng, Jian-Ping.,...&Xu, Yan-Cheng.(2013).Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables.BMC PUBLIC HEALTH,13.
MLA Ji, Li-Nong,et al."Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables".BMC PUBLIC HEALTH 13(2013).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Ji, Li-Nong]'s Articles
[Lu, Ju-Ming]'s Articles
[Guo, Xiao-Hui]'s Articles
百度学术
百度学术Similar articles in
[Ji, Li-Nong]'s Articles
[Lu, Ju-Ming]'s Articles
[Guo, Xiao-Hui]'s Articles
必应学术
必应学术Similar articles in
[Ji, Li-Nong]'s Articles
[Lu, Ju-Ming]'s Articles
[Guo, Xiao-Hui]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.